^
    CANCER:

    Kidney Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    bevacizumab-adcd
    Krabeva (bevacizumab biosimilar)
    bevacizumab-bvzr
    		0
    VEGF-A inhibitor
    bevacizumab-maly
    Aybintio (bevacizumab biosimilar)
    bevacizumab-awwb
    bevacizumab
    bevacizumab-tnjn
    nivolumab
    PD1 inhibitor
    		1
    PD1 inhibitor
    pembrolizumab
    dostarlimab-gxly
    toripalimab-tpzi
    cabozantinib tablet
    		2
    Multi-tyrosine kinase inhibitor
    pazopanib
    cabozantinib capsule
    midostaurin
    mTOR inhibitor
    		3
    mTOR inhibitor
    everolimus
    temsirolimus
    4
    IFNα stimulant, VEGF-A inhibitor
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    bevacizumab + pegylated interferon α -2a
    pembrolizumab + axitinib
    		5
    VEGFR inhibitor, PD1 inhibitor
    toripalimab-tpzi + axitinib
    sintilimab + axitinib
    6
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    7
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    8
    c-MET inhibitor
    c-MET inhibitor
    savolitinib
    9
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    10
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    11
    HIF-2α inhibitor
    belzutifan
    12
    VEGFR inhibitor
    VEGFR inhibitor
    axitinib
    13
    VEGF-A inhibitor, mTOR inhibitor
    bevacizumab + everolimus
    14
    EGFR inhibitor
    erlotinib
    15
    ALK inhibitor
    crizotinib
    alectinib
    PD-L1 inhibitor
    		16
    PD-L1 inhibitor
    atezolizumab
    avelumab
    17
    PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + cabozantinib tablet
    18
    AXL inhibitor, GAS6 inhibitor
    AVB-500
    19
    HLA G-targeted CAR-T immunotherapy
    IVS-3001
    20
    CD70-targeted CAR-T immunotherapy
    ALLO-316
    21
    PARP inhibitor
    olaparib
    talazoparib
    22
    Tubulin inhibitor
    vinblastine
    23
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    24
    PD-L1 inhibitor, c-MET inhibitor
    durvalumab + savolitinib
    25
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    26
    FGFR inhibitor
    ABSK091
    27
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    28
    PRMT5 inhibitor
    AMG 193
    29
    HDAC inhibitor
    vorinostat
    30
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    pembrolizumab + INCB024360
    31
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    32
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    33
    HIF-2α antagonist
    MK-3795
    34
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    35
    VEGF-A inhibitor, PI3Kγ inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    36
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    37
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    38
    Glutamate inhibitor
    Glutamate inhibitor
    39
    Immunotherapy
    Immunotherapy
    40
    VEGF inhibitor
    VEGF inhibitor
    41
    VEGFR inhibitor, Immunotherapy
    Immunotherapy + VEGFR inhibitor
    42
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    43
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    44
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    45
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    46
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    47
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    48
    CD122 agonist, IL-2 stimulant
    aldesleukin
    49
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    50
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    51
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    52
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
    ABT-869
    53
    AXL inhibitor, Multi-tyrosine kinase inhibitor, GAS6 inhibitor
    cabozantinib tablet + AVB-500
    54
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    55
    ATR inhibitor
    M6620
    56
    Ionizing radiation emitter, CD37 inhibitor
    177Lu-satetraxetan-lilotomab
    57
    DNA methylation inhibitor
    TdCyd
    58
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    59
    FGFR4 inhibitor
    BLU 9931
    60
    DNA synthesis inhibitor
    cisplatin
    61
    PRC2 inhibitor
    MRTX2219
    62
    AKT inhibitor
    GSK690693
    63
    NF-κB inhibitor, SYK inhibitor
    BAY-61-3606
    64
    pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + 4-methylumbelliferone
    65
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    66
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    67
    CDH6-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    CUSP06
    68
    pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sorafenib + sunitinib
    69
    TGM2 inhibitor
    MD102
    70
    RAC1 inhibitor
    NSC23766
    71
    MCL1 inhibitor
    PRT1419
    72
    CYP17A1 inhibitor
    abiraterone acetate
    73
    HER3 inhibitor, α radiation emission
    Ac-225 ErbB3 targeted radiotherapy
    74
    UCHL1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + 6RK73
    No biomarker
    MET amplification
    MET mutation
    MET fusion
    MET expression
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    PBRM1 mutation
    PBRM1 overexpression
    PBRM1 deletion
    PBRM1 negative
    PBRM1 underexpression
    MTOR mutation
    KDR rs2071559
    KDR C482R
    MTOR overexpression
    MTOR Q2223K
    KDR expression
    KDR overexpression
    RNASET2 overexpression
    FLT1 rs9554320
    FLT1 expression
    FLT1 overexpression
    AXL-L
    HLA-G positive
    ROBO3 mutation
    ARID1A mutation
    AXL overexpression
    AXL expression
    VHL mutation
    ALK rearrangement
    PD-1 expression
    HMOX1-L
    VCP-TFE3 fusion
    TSC2 H1620R + TSC2 Y1650C
    FH mutation
    HMOX1 expression
    TSC2 mutation
    TSC1 deletion
    TSC1 mutation
    FH deletion
    HGF expression
    BAP1 negative
    HGF-L
    BAP1 I696T
    TFE3 translocation
    FH negative
    HGF elevation
    BAP1 mutation
    PD-1 elevation
    BAP1 deletion
    VHL promoter methylation
    VHL deletion
    PDGFRA expression
    MSI-H/dMMR
    BRCA1 mutation
    BRCA2 mutation
    KIM1 expression
    FLCN mutation
    HDAC2 expression
    ERVE-4 expression
    HAVCR2 expression
    SPP1-L
    CXCL8-L
    IL6-L
    IL18 expression
    ANGPT2 expression
    TIMP1 expression
    CSF1 expression
    VEGFA expression
    CXCL9 expression
    IL18BP expression
    SYNE1 mutation
    CDKN2A mutation
    CEACAM1 overexpression
    CXCL10 overexpression
    CA9 expression
    CD31 expression
    GNAQ mutation
    IKZF2-L
    KDM5C mutation
    CD8 expression
    HIF1A expression
    LRP1B mutation
    ELTD1 expression
    IL6R L
    IL6ST elevation
    TFEB translocation
    PCSK9 underexpression
    EWSR1-POU5F1 fusion
    KMT2C mutation
    LDH elevation
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    PARP1 underexpression + PBRM1 mutation
    PTTG1 overexpression
    TNFRSF9 elevation
    PD-L1 expression + CD14 positive
    LAG3 positive + CD4 positive
    TNFRSF9 positive + CD8 positive
    TNFRSF9 positive + CD4 positive
    NF2 mutation
    FOLH1 overexpression
    KHDRBS1 overexpression
    PECAM1 underexpression
    CD3G overexpression
    NCAM1 overexpression
    CD4 underexpression
    ISLR overexpression
    AXL elevation + GAS6 elevation
    PYCR1 underexpression
    TNFRSF18-H
    MTAP deletion
    TLR3 overexpression
    WDR72 overexpression + PBRM1 mutation
    WDR72 overexpression
    PBRM1 mutation + SETD2 mutation
    ARID2 H1495fs*8
    SMARCB1 deletion
    TERT promoter mutation
    BRAF mutation
    miR-138 underexpression + miR-497 overexpression
    SETD2 mutation + TP53 mutation
    CXCL10 elevation
    CXCL8 elevation
    VEGFA elevation
    KIM1 elevation
    IL6 elevation
    TERT overexpression
    SETD2 mutation
    SETD2 deletion
    CDKN2A deletion
    VEGFA overexpression
    AP positive signature
    Low NLR
    Low MLR
    BONSAI high signature
    DDR
    IFNG gene signature overexpression
    Immune response prediction signature
    T-cell-inflamed GEP signature
    BBOX1 underexpression
    CDH6 expression
    KAT6A-NRG1 fusion
    HAS3 expression
    DAPK1 underexpression
    miR-155 underexpression
    SMARCA4 mutation
    KDM6A mutation
    CCNE1 amplification
    CTBP1 deletion
    ACRBP amplification
    GNAS amplification
    LRP10 deletion
    SULT1A3 amplification
    VEGFD overexpression
    UGT1A9 expression
    ADCYAP1 deletion
    TP53 mutation
    PAI1 elevation
    CD44 expression
    CD44 positive
    NT5E overexpression
    IL13RA2 overexpression
    IL7 elevation
    TET2 deletion + DNMT3A mutation
    CXCR4 overexpression
    TGM2 overexpression
    CXCL12 elevation
    PTEN deletion
    PRCC-TFE3 fusion
    TMB-H
    MTA2 overexpression
    PGF overexpression
    VEGFC underexpression
    PDGFA underexpression
    FLT4 overexpression
    TNFSF13B elevation
    CXCL13 elevation
    CD27 overexpression
    SPI1 overexpression
    Chr del(9)(p21.3)
    AXL overexpression + PD-L1 expression
    VEGFB overexpression
    DDX39B overexpression
    CXCL11 elevation
    CD276 expression
    TERC overexpression
    DKC1 overexpression
    HLA-A*03
    NUSAP1 overexpression
    CD70 expression
    FGFR4 amplification
    ERBB3 expression
    PLK1 overexpression
    MCAM overexpression
    TP53 expression
    EPAS1 G323E
    EPAS1 S304M
    EPAS1 overexpression
    FGFR1 overexpression
    LAG3 expression
    CCL4 elevation
    AR-V7 positive